2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Anis Hamid, MBBS, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer.
Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer (mHSPC).
In terms of development of a more precise way of treating patients with mHSPC, the data available at this stage is just related to gene expression profiling, says Hamid. What the field really wants to know is other biological information, mainly what is happening with the tumor genomics, what the mutational characteristics of these tumors that might be affecting prognosis are, or the predictive effects hypothesized with certain genomic alterations.
There are layers of biological information about genomics, such as epigenomics how DNA methylation may affect treatment response or prognosis. Investigators hope to integrate multiple layers of biological information across independent cohorts to get a multidimensional view of the biomarkers that might eventually guide precision care for patients with mHSPC, concludes Hamid.